267 related articles for article (PubMed ID: 26657151)
41. The tyrosine 343 residue of nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) is important for its interaction with SHP1, a cytoplasmic tyrosine phosphatase with tumor suppressor functions.
Hegazy SA; Wang P; Anand M; Ingham RJ; Gelebart P; Lai R
J Biol Chem; 2010 Jun; 285(26):19813-20. PubMed ID: 20424160
[TBL] [Abstract][Full Text] [Related]
42. Crizotinib enhances anti-CD30-LDM induced antitumor efficacy in NPM-ALK positive anaplastic large cell lymphoma.
Wang R; Li L; Duan A; Li Y; Liu X; Miao Q; Gong J; Zhen Y
Cancer Lett; 2019 Apr; 448():84-93. PubMed ID: 30742941
[TBL] [Abstract][Full Text] [Related]
43. Transcripts of the npm-alk fusion gene in anaplastic large cell lymphoma, Hodgkin's disease, and reactive lymphoid lesions.
Elmberger PG; Lozano MD; Weisenburger DD; Sanger W; Chan WC
Blood; 1995 Nov; 86(9):3517-21. PubMed ID: 7579458
[TBL] [Abstract][Full Text] [Related]
44. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1.
Pulford K; Lamant L; Morris SW; Butler LH; Wood KM; Stroud D; Delsol G; Mason DY
Blood; 1997 Feb; 89(4):1394-404. PubMed ID: 9028963
[TBL] [Abstract][Full Text] [Related]
45. Pathobiology of ALK+ anaplastic large-cell lymphoma.
Amin HM; Lai R
Blood; 2007 Oct; 110(7):2259-67. PubMed ID: 17519389
[TBL] [Abstract][Full Text] [Related]
46. The ALK inhibitor ASP3026 eradicates NPM-ALK⁺ T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model.
George SK; Vishwamitra D; Manshouri R; Shi P; Amin HM
Oncotarget; 2014 Jul; 5(14):5750-63. PubMed ID: 25026277
[TBL] [Abstract][Full Text] [Related]
47. A "liaison dangereuse" between AUF1/hnRNPD and the oncogenic tyrosine kinase NPM-ALK.
Fawal M; Armstrong F; Ollier S; Dupont H; Touriol C; Monsarrat B; Delsol G; Payrastre B; Morello D
Blood; 2006 Oct; 108(8):2780-8. PubMed ID: 16835382
[TBL] [Abstract][Full Text] [Related]
48. Inhibition of tyrosine kinase activity induces caspase-dependent apoptosis in anaplastic large cell lymphoma with NPM-ALK (p80) fusion protein.
Ergin M; Denning MF; Izban KF; Amin HM; Martinez RL; Saeed S; Alkan S
Exp Hematol; 2001 Sep; 29(9):1082-90. PubMed ID: 11532349
[TBL] [Abstract][Full Text] [Related]
49. Methotrexate significantly induces apoptosis by inhibiting STAT3 activation in NPM-ALK-positive ALCL cells.
Uchihara Y; Komori R; Tago K; Tamura H; Funakoshi-Tago M
Biochem Pharmacol; 2019 Dec; 170():113666. PubMed ID: 31654627
[TBL] [Abstract][Full Text] [Related]
50. NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma.
Galietta A; Gunby RH; Redaelli S; Stano P; Carniti C; Bachi A; Tucker PW; Tartari CJ; Huang CJ; Colombo E; Pulford K; Puttini M; Piazza RG; Ruchatz H; Villa A; Donella-Deana A; Marin O; Perrotti D; Gambacorti-Passerini C
Blood; 2007 Oct; 110(7):2600-9. PubMed ID: 17537995
[TBL] [Abstract][Full Text] [Related]
51. Identification and characterization of a nuclear interacting partner of anaplastic lymphoma kinase (NIPA).
Ouyang T; Bai RY; Bassermann F; von Klitzing C; Klumpen S; Miething C; Morris SW; Peschel C; Duyster J
J Biol Chem; 2003 Aug; 278(32):30028-36. PubMed ID: 12748172
[TBL] [Abstract][Full Text] [Related]
52. The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration.
Voena C; Conte C; Ambrogio C; Boeri Erba E; Boccalatte F; Mohammed S; Jensen ON; Palestro G; Inghirami G; Chiarle R
Cancer Res; 2007 May; 67(9):4278-86. PubMed ID: 17483340
[TBL] [Abstract][Full Text] [Related]
53. Recombinant expression, characterization, and quantification in human cancer cell lines of the Anaplastic Large-Cell Lymphoma-characteristic NPM-ALK fusion protein.
Kourentzi K; Crum M; Patil U; Prebisch A; Chavan D; Vu B; Zeng Z; Litvinov D; Zu Y; Willson RC
Sci Rep; 2020 Mar; 10(1):5078. PubMed ID: 32193476
[TBL] [Abstract][Full Text] [Related]
54. Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity.
Bai RY; Dieter P; Peschel C; Morris SW; Duyster J
Mol Cell Biol; 1998 Dec; 18(12):6951-61. PubMed ID: 9819383
[TBL] [Abstract][Full Text] [Related]
55. MiR-29a down-regulation in ALK-positive anaplastic large cell lymphomas contributes to apoptosis blockade through MCL-1 overexpression.
Desjobert C; Renalier MH; Bergalet J; Dejean E; Joseph N; Kruczynski A; Soulier J; Espinos E; Meggetto F; Cavaillé J; Delsol G; Lamant L
Blood; 2011 Jun; 117(24):6627-37. PubMed ID: 21471522
[TBL] [Abstract][Full Text] [Related]
56. miR-497 suppresses cycle progression through an axis involving CDK6 in ALK-positive cells.
Hoareau-Aveilla C; Quelen C; Congras A; Caillet N; Labourdette D; Dozier C; Brousset P; Lamant L; Meggetto F
Haematologica; 2019 Feb; 104(2):347-359. PubMed ID: 30262555
[TBL] [Abstract][Full Text] [Related]
57. TrkA is a binding partner of NPM-ALK that promotes the survival of ALK
Shi W; George SK; George B; Curry CV; Murzabdillaeva A; Alkan S; Amin HM
Mol Oncol; 2017 Sep; 11(9):1189-1207. PubMed ID: 28557340
[TBL] [Abstract][Full Text] [Related]
58. The t(2;5) in human lymphomas.
Kadin ME; Morris SW
Leuk Lymphoma; 1998 Apr; 29(3-4):249-56. PubMed ID: 9684923
[TBL] [Abstract][Full Text] [Related]
59. Model of inhibition of the NPM-ALK kinase activity by herbimycin A.
Turturro F; Arnold MD; Frist AY; Pulford K
Clin Cancer Res; 2002 Jan; 8(1):240-5. PubMed ID: 11801565
[TBL] [Abstract][Full Text] [Related]
60. Mapping of genomic t(2;5)(p23;q35) break points in patients with anaplastic large cell lymphoma by sequencing long-range PCR products.
Luthra R; Pugh WC; Waasdorp M; Morris W; Cabanillas F; Chan PK; Sarris AH
Hematopathol Mol Hematol; 1998; 11(3-4):173-83. PubMed ID: 9844824
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
